Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
UAB Medical Genomics Laboratory, |
RCV001007766 | SCV001167449 | pathogenic | Neurofibromatosis, type 1 | 2020-01-20 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001007766 | SCV001374566 | pathogenic | Neurofibromatosis, type 1 | 2023-03-07 | criteria provided, single submitter | clinical testing | This sequence change falls in intron 41 of the NF1 gene. It does not directly change the encoded amino acid sequence of the NF1 protein. It affects a nucleotide within the consensus splice site. This variant is not present in population databases (gnomAD no frequency). This variant has been observed in individual(s) with clinical features of neurofibromatosis type I (PMID: 18546366, 24232412, 30308447; Invitae). This variant is also known as c.6428-3C>G. ClinVar contains an entry for this variant (Variation ID: 816775). Variants that disrupt the consensus splice site are a relatively common cause of aberrant splicing (PMID: 17576681, 9536098). Studies have shown that this variant is associated with altered splicing resulting in unknown protein product impact (PMID: 18546366, 24232412). For these reasons, this variant has been classified as Pathogenic. |
Institute of Medical Genetics and Applied Genomics, |
RCV001268487 | SCV001447455 | likely pathogenic | not provided | 2020-10-23 | criteria provided, single submitter | clinical testing | |
Gene |
RCV001268487 | SCV002007228 | pathogenic | not provided | 2022-10-04 | criteria provided, single submitter | clinical testing | Non-canonical splice site variant demonstrated to result in skipping of exon 42 (Pros 2008); Not observed at significant frequency in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 25525159, 18546366, 24232412, 32126153, 30308447) |
Genome- |
RCV001007766 | SCV002560182 | likely pathogenic | Neurofibromatosis, type 1 | 2022-03-15 | criteria provided, single submitter | clinical testing |